Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

319.55 -44.21 (-12.15%)
Delayed Quote Updated: 3:41 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Natera Announces Leadership Transition
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Third Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
From Natera, Inc.
Via Business Wire
News headline image
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter Results on November 5, 2026
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
From Natera, Inc.
Via Business Wire
News headline image
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
From Natera, Inc.
Via Business Wire
News headline image
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
From Natera, Inc.
Via Business Wire
News headline image
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
From Natera, Inc.
Via Business Wire
News headline image
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
From Natera, Inc.
Via Business Wire
News headline image
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Second Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Second Quarter Results on August 6, 2026
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
From Natera, Inc.
Via Business Wire
News headline image
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.